ImmunoCellular Therapeutics is a clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. IMUC is conducting a phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. The company’s pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. For more information visit the company’s Web site at www.IMUC.com
Let us hear your thoughts below: